PMID int64 35.7M 36.4M | Title/Abstract stringlengths 22 8.78k | MeshTerms stringlengths 7 101 | SemanticTypes stringlengths 4 64 |
|---|---|---|---|
36,254,654 | prognost factor influenc postop air bone gap stape surgeri otosclerosi osteodystroph diseas otic capsul determin conduct mix hear loss success treat stapedotomi aim present multicentr retrospect studi identifi prognost factor relat better auditori outcom stape surgeri | D010040;D013201 | T061;T047 |
36,254,653 | biofilm characterist manag skin flap infect follow cochlear implant studi aim assess frequenc bacteriolog biofilm characterist manag skin flap infect sfi follow cochlear implant ci | D019929;D003054;D013203 | T061;T047;T074 |
36,254,652 | potenti serolog biomark inner ear patholog otolin goal studi determin whether level otolin protein whose express high restrict inner ear increas bodi fluid patient inner ear disord comparison healthi subject | D007758;D016326;D003639;D008575;D020338 | T123;T184;T116;T033;T023;T047 |
36,254,651 | multidimension voic assess lee silverman voic therapi lsvt parkinson diseas investig effect lee silvermann voic treatment lsvt improv prosodi patient parkinson diseas medium term follow | D010300;D014831;D014832 | T033;T047;T040 |
36,254,650 | enhanc recoveri surgeri era protocol head neck cancer match pair analysi studi aim describ prospect implement enhanc recoveri surgeri era protocol italian tertiari academ centr | D000080482;D006258 | T061;T191 |
36,254,649 | nasal glial heterotopia systemat review literatur case report eterotopia glial nasal una review sistematica della letteratura e case report | D009668;D009669 | T047;T191 |
36,254,629 | natur frequenc time pediatr sedat advers event natur frequenc pediatr sedat advers event ae well describ howev time specif ae induct procedur recoveri phase sedat remain unknown object describ natur frequenc time ae hypothes ae would start induct phase | D000758;D000402 | T061;T047;T046 |
36,254,627 | day old male respiratori distress acut onset hypotonia day old full term previous healthi male present decreas activ oral intak found grunt hypoxem examin respiratori pathogen panel posit rhinovirus diagnos presum bronchiol neurolog exam admiss normal respiratori failur escal high flow nasal cannula bilevel posit airway pressur upon admiss start ceftriaxon vancomycin await cultur data hospit day requir escal respiratori support examin time notabl new hypotonia bilater upper lower extrem sluggish pupil bilater exotropia intermitt vertic nystagmus absent moro reflex develop focal seizur comput tomographi brain demonstr simpl right otomastoid seizur attribut serum sodium mmoll set syndrom inappropri antidiuret hormon secret thought secondari viral bronchiol howev patient sodium correct normal rang continu neurolog deficit examin given persist hypotonia respiratori failur atyp expect cours viral bronchiol patient underw extens neurolog infecti workup ultim reveal surpris diagnosi | D001990;D012131;D012128 | T047;T046 |
36,254,626 | two photon absorpt triplet excit state quench near ir region aza bodipi photosensit via triphenylamin moieti despit heavi bromin atom aza bodipi compound methoxi group triphenylamin moieti posit without heavi bromin atom posit design synthes chemic structur novel compound fulli character use h nmr c nmr ftir hrms tof esi techniqu steadi state absorpt emiss featur investig analyz ground state interact effect triphenylamin moieti bromin atom charg transfer dynam two photon absorpt tpa properti investig use femtosecond transient absorpt spectroscopi measur open apertur oa z scan experi respect contrari popular belief compound contain heavi bromin atom triphenylamin moieti demonstr triplet transit sinc triphenylamin moieti high electron donat properti long conjug length exhibit intramolecular charg transfer ict featur electron donat moieti aza bodipi core addit conclud excit state lifetim shorten presenc bromin atom triphenylamin moieti result rather interest sinc triplet excit state quench triphenylamin moieti despit presenc heavi bromin atom perform oa z scan experi reveal aza bodipi compound contain bromin atom higher tpa cross section valu gm due effici intramolecular charg transfer compar without bromin atom gm addit theoret calcul found charg transfer percentag ct strongest compound contain bromin atom | D017319;D001372 | T121;T039;T109 |
36,254,609 | self assembl novel multicompon polyoxometal base tetrahedr superclust high catalyt activ thioether oxid glamor polyoxometal pom base macromolecul contain tetrahedr superclust hbiz p co movo p movo pbp co movmovio ca h situ self assembl three novel compon pbp co mo p co mo p movo p mo p co movo p co mo respect knowledg repres first tetrahedr superclust contain basket like pom structur besid macromolecul exhibit high catalyt activ reusabl oxid thioether sulfoxid | D013440;D017973 | T104;T197;T109 |
36,254,608 | associ cdh methyl esophag cancer risk meta analysi bioinformat studi aim evalu associ cdh methyl esophag cancer ec risk | D019295;D004938 | T191;T091 |
36,254,607 | applic perovskit bioimag state art futur develop recent develop perovskit base nanocryst sustain applic bioimag clinic diagnost becom activ area research hybrid zero dimension quantum dot qds perovskit along varieti characterist featur specif non linear optoelectron properti attract enorm research attent characterist tune type cation anion ratio use host perovskit carrier dope chemic modif addit altern control optic magnet radiodiagnost | D045663 | T073 |
36,254,604 | pharmacotherapi manag symptom machado joseph diseas machado joseph diseas spinocerebellar ataxia type scamjd lead caus autosom domin ataxia worldwid slowli progress disabl disord ataxia main clinic featur addit motor non motor manifest may found mani manifest amen pharmacolog treatment may impact qualiti life affect subject | D017827;D012893 | T047;T048 |
36,254,595 | deoxyfluorin tune aggreg cellulos chitin oligosaccharid highlight role specif hydroxyl group crystal process cellulos chitin abund structur polysaccharid exploit natur larg number applic thank crystallin chemic modif common employ tune polysaccharid physic mechan properti generat heterogen mixtur thus effect modif well understood molecular level work examin deoxyfluorin site pattern impact solubl aggreg well defin cellulos chitin oligom deoxyfluorin increas solubl water lower crystallin cellulos oligom chitin much less affect modif ohf substitut also highlight role specif hydroxyl group crystal process work provid guidelin design cellulos chitin base materi similar approach imagin prepar cellulos chitin analogu capabl withstand enzymat degrad | D002686;D002482 | T123;T122;T109 |
36,254,593 | covid vaccin distribut global north south discret choic experi six european countri global distribut covid vaccin remain high unequ examin public prefer six european countri regard alloc covid vaccin global south global north | D000086382;D014612 | T129;T121;T116;T067;T047 |
36,254,592 | non invas classif macrophag polaris p flim machin learn studi utilis fluoresc lifetim imag nad p h base cellular autofluoresc non invas modal classifi two contrast state human macrophag proxi govern metabol state macrophag deriv human blood circul monocyt polaris use establish protocol metabol challeng use small molecul valid respond metabol action extracellular acidif oxygen consumpt larg field view imag individu polaris macrophag obtain use fluoresc lifetim imag microscopi flim challeng real time small molecul perturb metabol imag uncov flim paramet pronounc action carbonyl cyanid p trifluoromethoxyphenylhydrazon fccp strong stratifi phenotyp polaris human macrophag howev perform impact donor variabl analys data singl cell level stratif paramet eman full field view singl cell flim approach serv basi machin learn model appli random forest model identifi three strong govern flim paramet achiev area receiv oper characterist curv roc auc valu bag obb error rate classifi human macrophag full field view imag conclud p flim integr machin learn model show power techniqu analysi human macrophag metabol polaris full fov singl cell level | D008264;D009243 | T123;T121;T025;T114 |
36,254,591 | oleocanth induc death preferenti tumor hematopoiet cell caspas depend independ mechan oliv oil key compon high cardiovascular protect mediterranean diet oleocanth olc one interest phenol present virgin oliv oil form secoiridoid ligustrosid process oliv yield oil anti inflammatori anti oxid properti identifi short olc isol follow discoveri anti tumor activ non hematopoiet cell lineag scarciti tissu potenti target olc analyz far unresolv mechan olc anti tumor properti use panel cell line belong tissu lineag carri detail examin target pathway lead cell growth inhibit death found olc inhibit cell prolifer induc apoptot death reveal sub g cell cycl analys annexin v stain lineag analyz except lung carcinoma cell line hematopoiet tumor cell line untest sensit olc treatment wherea non transform cell signific resist cell death specif olc mediat caspas activ confirm block experi use transfect overexpress anti apoptot gene olc trigger typic mediat intrins apoptot pathway product reactiv oxygen speci mitochondri membran depolar complet blockad caspas howev result parallel abrog annexin v stain thus suggest complex mechan involv trigger olc mediat cell death result demonstr olc preferenti target hematopoiet tumor cell line support cell death mediat caspas depend independ mechan | D020169;D019337 | T191;T126;T116 |
36,254,587 | cycloaddit alkoxynaphthalen azaoxyallyl cation access benzo e indolon reaction alkoxynaphthalen situ form azaoxyallyl cation report ambient reaction condit cycloaddit reaction follow aryl c omec oet bond cleavag produc varieti benzo e indolon deriv base isol intermedi control experi previous result possibl mechan drawn reduct n bond benzo e indolon deriv manifest possibl function product toward biolog import heterocycl molecul | D061565 | T067 |
36,254,582 | sensit bioanalyt method telomeras activ detect cancer biomark telomeras enzym protect length telomer ad guanin rich repetit sequenc tumor gamet stem cell telomeras activ exert telomeras activ cancer biomark therapeut diagnosi approach number studi concentr discoveri telomeras activ report bioanalyt devic comparison test numer advantag includ low expens simplic excel sensit specif articl review recent studi subject various bioanalyt method base differ nanomateri optic electrochem quartz crystal microbal qcm promin analyt techniqu mention paper | D019098;D049329;D009369 | T191;T126;T116;T073 |
36,254,578 | lrrk mediat ndel phosphoryl promot cilia disassembl via dynein driven retrograd intraflagellar transport primari cilia antenna like organell regul growth develop via extracellular signal howev molecular mechan under cilia dynam particular regul disassembl well understood show leucin rich repeat kinas lrrk play role regul cilia disassembl deplet lrrk impair primari cilia resorpt follow serum stimul cultur cell polo like kinas plk play import role process ciliari resorpt plk phosphoryl lrrk primari cilia base result activ identifi nuclear distribut protein nude like ndel known posit regul cilia disassembl target lrrk phosphoryl wherea lrrk phosphoryl ndel ser promot ndel interact intermedi chain cytoplasm dynein also crucial trigger ciliari resorpt dynein driven retrograd intraflagellar transport find provid evid novel plk lrrk ndel pathway regul cilia disassembl | D004398;D002923 | T026;T123;T126;T116 |
36,254,577 | self assembl small molecul adjuv antigen nano carrier effect co deliveri antigen immun potenti adjuv high degre antigen present two major challeng develop subunit vaccin address issu conjug peptid antigen cholicamid self assembl small molecul adjuv co assembl conjug cholicamid achiev high level cytokin induct mhc class ii peptid present | D000276;D000941 | T129;T121 |
36,254,571 | fgf overrid key pro fibrot featur bone marrow stromal cell isol modic type chang patient extens extracellular matrix product increas cell matrix adhes bone marrow stromal cell bmscs hallmark fibrot alter vertebr bone marrow known modic type chang mc mc associ non specif chronic low back pain identifi treatment target mc vitro studi use patient bmscs import reveal patholog mechan cultur bmscs fibroblast growth factor fgf wide use howev fgf shown suppress matrix synthesi various stromal cell popul aim present studi investig whether fgf affect vitro studi fibrot pathomechan mc deriv bmscs transcriptom chang chang cell matrix adhes mc deriv bmscs compar intra patient control bmscs respons fgf rna sequenc quantit real time polymeras chain reaction reveal pro fibrot gene pathway detect mc deriv bmscs cultur presenc fgf addit signific increas cell matrix adhes mc deriv bmscs abolish presenc fgf conclus data demonstr fgf overrid key pro fibrot featur mc bmscs vitro usag fgf supplement media studi fibrot mechan critic evalu could overrid normal domin biolog biophys cue | D016222;D059630 | T123;T116;T025 |
36,254,564 | paleolimnolog context ecolog vulner freshwat ecosystem sabl island nation park reserv canada protect area requir long term monitor understand influenc extent ecosystem stress inform manag conserv decis long term data alway avail paleolimnolog method offer way extend knowledg past environment condit necessari use context remedi examin four sediment core addit surfac sediment pond locat sabl island nation park reserv canada sinpr long term ecolog chang vulner disturb well defin develop paleolimnolog approach assess environment vulner use biolog indic diptera chironomida shift environ infer shift chironomid assemblag time analysi surfac sediment show four distinct assemblag type reflect four differ habitat condit primarili repres presenc glyptotendip chironomus microtendip dicrotendip differ habitat condit time base result compar biostratigraph analysi sediment core four pond found two pond larg shift chironomid assemblag associ chang habitat time two other expos influenc eros influx sand dune find establish baselin histor chang sinpr broaden scope long term monitor essenti defin goal manag conserv ecolog integr sabl island | D002683;D045969 | T015;T204 |
36,254,548 | atyp scleroderma like chronic gvhd liver transplant patient clinic mri correl dear editor cutan chronic graft versus host diseas cgvhd patholog process consist donor deriv cell aim antigen recipi exhibit larg rang clinic present resembl morphea deep sclerosisfasci character inflamm progress dermal hypoderm fibrosi although classic scleroderma like lesion cgvhd nummular irregular plaqu linear bundl associ hypo hyperpigment report atyp case ulcer present case report morphea like scleroderma like cgvhd ulcer appear liver transplant lt magnet reson imag mri correl found literatur case report ten month lt due end stage cirrhosi associ multifoc hepatocarcinoma hcc year old man immunosuppress therapi tacrolimus mg everolimus mg present clinic skin lesion right scapular region observ flat ulcer plaqu area sclerosi minim necrosi well defin slight erythemat margin figur palpat plaqu hard consist slight pain skin lesion preced subject discomfort sting sensat seven month onset gradual lesion develop start small flat oval purplish plaqu associ progress increas pain patient deni dysphagia retrostern heartburn raynaud phenomenon arthralgia dyspnea previous mri figur b show subcutan muscl edema blood test show abnorm liver function index due extrahepat cholestasi c reactiv protein erythrocyt sediment rate leukocyt within normal rang self reactiv antibodi negat histolog examin figur b identifi rare dyskeratot keratinocyt basal lymphocyt infiltr dermal dens fibrosi disappear skin appendag larg fibrous septa adipos panniculus led diagnosi sclerodermamorphea base patient clinic histori diagnosi graft versus host diseas scleroderma like post liver transplant establish lesion treat topic applic clobetasol day use system immunosuppress therapi order prevent hcc recurr patient current clinic follow identifi worsen neoplast degener case discuss cutan cgvhd often present clinic ulcer evolut context fibrosi diffus skin atrophi rare initi appear well delimit ulcer plaqu case ulcer found literatur patient undergo hematopoiet stem cell transplant hsct associ highest risk develop gvhd lt quit low incid knowledg first case report scleroderma like cgvhd lesion ulcer appear lt patient underw two mris post transplant follow allow us evalu deep diseas evolut weight mri figur c perform approxim year transplant demonstr fibrous septa subcutan fat fascial thicken associ muscl hypotrophi edema previous mri perform seven month transplant alreadi show subcutan tissu fascial edema highlight activ inflamm evid suggest mri could identifi lesion locat clinic manifest provid opportun interven prompt best knowledg first report case cgvhd atyp scleroderma like present liver transplant patient whose clinic mri correl trace suggest support result previous studi evalu mri perform assess diseas extent activ well therapeut respons hsct | D006086;D016031;D012594;D012871 | T061;T047 |
36,254,547 | decreas arteri vascular tone small arteri sever hidraden suppurativa studi use finger photopulseplethysmographi previous studi found associ chronic inflammatori disord eg psoriasi rheumatoid arthriti inflammatori bowel diseas increas vascular stiff psoriasi hidraden suppurativa hs believ share comorbid pathophysiolog despit morpholog differ manifest skin order evalu putat associ chronic inflammatori skin diseas hs arteri stiff observ cross section retrospect studi carri part danish general suburban popul studi gesus patient hs general popul repres mild hs tabl patient hs hospit base patient clinic repres sever hs tabl control underw measur arteri vascular tone stiff use photoplethysmographi puls trace pca micro medic ltd kent uk method puls trace valid correl intra arteri sens techniqu simpl cost effect screen method analys perform use sas studi accept ethic committe region zealand project number sj sj sj denmark result reflect index ri express arteri vascular tone stiff small arteri raw data show signific lower ri hs group group compar control result remain signific adjust confound age sex smoke metabol syndrom patient clinic hs group p popul hs group tabl stiff index si express arteri stiff larg arteri hs group show signific differ either si vascular age multivari analysi compar control tabl discuss studi suggest decreas vascular tone stiff small arteri may associ sever hs time found differ arteri stiff larg arteri signific patient clinic hs group popul hs group may reflect dose respons relationship vascular tone vascular smooth muscl cell small arteri depend compet vasodil vasoconstrictor specul inflamm hs may induc dysfunct balanc eg increas tnf alpha subsequ increas vasodil nitric oxid result lower arteri vascular tone observ addit mast cell increas hs possibl increas level vasodil histamin hs patient often suffer stress could increas sympathet activ therebi adrenalincortisol subsequ vasodil eg muscl peripher arteri collagen contain stiffer find lower vascular tone may also suggest differ elastin collagen ratio small arteri hs heal process hs lesion known involv scar format sinus tract may suggest hypothesi alter connect tissu studi found differ si express arteri stiff larg arteri hs control previous studi found associ hs myocardi infarct associ stroke peripher arteri stiff lower extrem mediumlarg arteri suggest region differ vascular bed hs major limit studi miss valu puls trace measur tabl creat possibl select bias although unabl draw clinic conclus believ result may contribut futur research complex hs cardiovascular risk profil studi suggest decreas vascular tone stiff small arteri may associ sever hs time found differ arteri stiff larg arteri signific patient clinic hs group popul hs group may reflect dose respons relationship vascular tone vascular smooth muscl cell small arteri depend compet vasodil vasoconstrictor specul inflamm hs may induc dysfunct balanc eg increas tnf alpha subsequ increas vasodil nitric oxid result lower arteri vascular tone observ addit mast cell increas hs possibl increas level vasodil histamin hs patient often suffer stress could increas sympathet activ therebi adrenalincortisol subsequ vasodil eg muscl peripher arteri collagen contain stiffer find lower vascular tone may also suggest differ elastin collagen ratio small arteri hs heal process hs lesion known involv scar format sinus tract may suggest hypothesi alter connect tissu studi found differ si express arteri stiff larg arteri hs control previous studi found associ hs myocardi infarct associ stroke peripher arteri stiff lower extrem mediumlarg arteri suggest region differ vascular bed hs major limit studi miss valu puls trace measur tabl creat possibl select bias although unabl draw clinic conclus believ result may contribut futur research complex hs cardiovascular risk profil | D017497;D009203;D011565;D020521 | T047 |
36,254,546 | torasemid induc vascular purpura cours eosinophil granulomatosi polyangi torasemid loop diuret molecul chemic similar sulphonamid describ eosinophil granulomatosi polyangi egpa trigger drug present case probabl first descript torasemid induc vascular purpura cours egpa diagnosi vascul follow identif drug may aggrav diseas year old patient admit depart dermatolog purpura like skin lesion upper lower extrem includ buttock lesion appear around ankl day admiss hospit start progress upward patient complain lower limb paresthesia pain comorbid includ bronchial asthma chronic sinus ischem heart diseas mild aortic stenosi arteri hypertens degen thorac spine diseas woman previous undergon nasal polypectomi twice constant regimen oral rosuvastatin mg per day spironolacton mg per day metoprolol mg per day inhal formoterol g per day ipratropium bromid g per day ten day prior admiss commenc torasemid dose mg per day prescrib general practition due high blood pressur doppler ultrasound upon admiss hospit exclud deep venal thrombosi laboratori test reveal leukocytosi thousand per mm eosinophilia elev plasma level c reactiv protein mg per l dimer ng per mm indirect immunofluoresc test identifi low titer antinuclear antibodi elev antineutrophil cytoplasm antibodi anca patient serum immunoblot found aim myeloperoxidas panca chest x ray show increas vascular lung mark high resolut comput tomographi reveal peribronchi glass ground opac microscop evalu skin biopsi taken lower limb show perivascular infiltr consist eosinophil neutrophil fragment neutrophil nuclei fibrin necrosi small vessel electromyographi perform lower limb weak highlight loss respons sural nerv well slow conduct veloc right tibial nerv common peron nerv clinic characterist skin lesion histopatholog suggest diagnosi egpa later confirm consult rheumatolog patient commenc prednison dose mg per kg bodi weight daili mycophenol mofetil daili dose g antihypertens therapi modifi torasemid replac spironolacton mg per day treatment result gradual regress skin lesion within week first report egpa date back author jacob churg lott strauss describ case seri patient sever asthma fever peripher blood eosinophilia granulomat vascul microscop evalu skin three histopatholog criteria propos churg strauss syndrom recogn eosinophil infiltr tissu necrot inflamm small medium vessel presenc extravascular granuloma observ togeth patient patient met three histopatholog criteria diagnosi diseas frequent delay despit overt clinic pictur lanham et al propos new diagnost criteria includ presenc bronchial asthma eosinophilia peripher blood smear thousand per mm sign vascul involv least two organ lung lanham criteria could also delay recognit syndrom involv intern organ american colleg rheumatolog therefor establish classif criteria includ presenc bronchial asthma migratori infiltr lung assess radiograph presenc abnorm paranas sinus polyp allerg rhiniti chronic inflamm mono polyneuropathi peripher blood eosinophilia leukocyt must eosinophil extravascular eosinophil infiltr histopatholog examin patient met criteria classifi churg strauss syndrom term egpa recommend defin patient churg strauss syndrom egpa condit low incid case per million morbid usual occur fifth decad life although case report egpa peopl year age could found pubm ovid medlin databas end etiopathogenesi diseas fulli explain far approxim patient posit panca role antibodi pathogenesi egpa remain unclear suspect mediat bind fc receptor mpo expos surfac neutrophil subsequ may activ neutrophil contribut damag vascular endothelium glomerulonephr neuropathi vascul common patient egpa detect panca compar seroneg patient least sever drug potenti may egpa strongest associ occurr egpa found use leukotrien receptor antagonist montelukast zafirlukast pranlukast although common use treatment asthma paradox one complic syndrom although relationship demonstr far occurr egpa intak drug group use present patient clear time relationship observ commenc torasemid onset symptom patient date three case leukocytoclast vascul report administr torasemid develop cutan symptom diseas within hour administr torasemid patient previous histori drug hypersensit disappear quick within day drug discontinu chemic structur torasemid similar molecul sulfonamid previous found trigger factor egpa drug belong group loop diuret classifi sulfonamid deriv comparison chemic structur torasemid sulphanilamid molecul present figur clear time relationship start administr torasemid occurr purpura like lesion suggest aggrav factor egpa patient coexist sever disord asthma nasal polyp symptom peripher neuropathi patient suggest egpa could develop year oral intak torasemid sudden onset skin symptom show torasemid possibl induc factor develop vascular purpura patient suffer egpa without previous cutan involv | D001249;D015267;D004802;D014890;D011693 | T184;T047 |
36,254,545 | morphea dermatofibrosarcoma protuberan dear editor morphea profunda mp chronic autoimmun diseas subtyp local scleroderma present clinic local discomfort due impair skin motil dermatofibrosarcoma protuberan dfsp rare soft tissu neoplasm infiltr dermi subcutan tissu also affect muscl bone finger like extens usual present trunk proxim extrem dfsp known indol clinic cours local aggress behavior high local recurr rate relat low risk metastat spread dfsp frequent aris middl age adult affect sex equal incid per peopl report case year old femal patient first present clinic age year due brownish atroph coin size lesion appear left side abdomen medic report indic biopsi perform previous occas histopatholog find confirm diagnosi mp aforement lesion abdomen grow slowli year patient final visit clinic year later notic two palpabl nodul develop within affect skin figur b clinic examin reveal indur ill defin plaqu measur cm partial atroph surfac central locat palpabl nodul measur mm deep biopsi lesion perform histopatholog immunohistochem analysi cd express confirm diagnosi dermatofibrosarcoma protuberan figur c comput tomographi scan thorax abdomen pelvic region subsequ perform reveal diseas progress complet excis tumor perform follow wide scar excis due narrow surgic margin mm diseas progress recurr note follow patient diseas free one year postop although etiolog dfsp unknown trauma hypothes predispos factor usual present trunk proxim extrem patient usual report diseas progress long period time rang sever month year tumor associ variabl color chang even proxim skin discolor often present slowli grow indur dermal plaqu firm nodul attach skin clinic difficult distinguish dfsp wide number diagnos includ morphea idiopath atrophoderma atroph scar anetoderma lipoatrophi cellular dermatofibroma fibrosarcoma malign fibrous histiocytoma atyp fibroxanthoma desmoplast melanoma kaposi sarcoma solitari fibrous tumor immunohistochemistri stain cd cell help differenti sinc spindl cell stain posit dfsp due alter dermal collagen histopatholog differenti diagnos dfsp includ lichen sclerosus atroph scar keloid well morphea atroph dermatofibroma undifferenti pleomorph sarcoma mainstay dfsp treatment tumor excis perform either wide local excis moh surgeri surgic margin cm sever studi confirm patient treat moh techniqu signific lower recurr rate due high number unsatisfactori primari excis wide free surgic margin import diseas control radiotherapi might consid therapeut option inoper tumor relaps well adjuv therapi primari excis excis posit margin furthermor recent find indic posit therapeut efficaci administr imatinib mesilat tyrosin kinas inhibitor due express pdgf clinic follow patient dfsp tumor excis perform everi six month first five year follow year interv thereaft year previous case report claim diagnosi dsfp common delay result slow tumor growth nonspecif initi clinic find best knowledg case first descript literatur dfsp develop within mp plaqu specul trauma repeat punch biopsi taken sclerot morpheaform plaqu may repres trigger develop dfsp anoth notabl clinic challeng surgic excis sinc major case present literatur mention unsatisfactori resect margin high risk local diseas recurr although complet excis neoplasm perform excis perform order provid wider resect margin surgic resect remain main treatment dermatofibrosarcoma protuberan main challeng achiev clean excis margin proper manag diseas continu follow import order prevent local recurr dermatofibrosarcoma protuberan potenti metastas | D018223;D018219;D012594;D012878 | T047;T191 |
36,254,544 | coexist lichen planus pemphigoid palmoplantar keratoderma unna thost atop dermat lichen planus pemphigoid lpp rare autoimmun blister diseas associ lichenoid skin chang unna thost palmoplantar keratoderma pkk type diffus palmoplantar keratoderma most affect palm hand sole feet usual begin earli childhood present uniqu case coexist lpp unna thost ppk atop dermat ad knowledg three report case lpp unna thost ppk report coexist unna thost pkk ad | D001327;D003876;D004485;D007645;D015776;D008010 | T019;T047 |
36,254,543 | sever protein loss month old exclus breastf infant atop dermat protein loss often result kidney intestin diseas protein lose enteropathi caus number serious potenti life threaten complic hypotens thrombocytosi electrolyt imbal cerebellar ischemia recent research suggest associ extrem sever atop dermat ad allerg enteropathi exclus breastf month old infant admit institut due failur thrive electrolyt imbal sever ad score atop dermat scorad admiss infant poor general condit dehydr malnourish bodyweight g z score exud erythemat morph scatter throughout bodi initi laboratori result show microcyt hypochrom anemia hypoalbuminemia hypogammaglobinemia thrombocytosi hyponatremia high valu total immunoglobulin e ige eosinophilia polysensit number nutrit inhal allergen demonstr exclus amino acid base formula introduc diet hospit cours patient develop superfici thrombophleb methicillin resist staphylococcus aureus mrsa bacteremia eosinophilia found small intestin biopsi sampl due sever hypogammaglobulinemia skin infect bacteremia differenti diagnosi includ primari immun defici stat defici dock defici pgm defici ipex avail immunolog test unremark exclus amino acid base formula diet continu infant topic corticosteroid wet dress therapi intraven immunoglobulin replac therapi gradual improv general condit introduct solid food start accord find allergi test month age patient gain weight skin status improv although frequent use topic corticosteroid necessari infect anemia thrombocytosi albumin immunoglobulin supplement longer requir main mechan protein loss infant extrem sever atop dermat probabl due damag skin partial due eosinophil inflamm small intestin immunoglobulin loss potenti physiolog transient hypogammaglobulinemia infant pose high risk sever potenti life threaten infect | D000361;D016470;D003876;D055624;D013922 | T047;T007 |
36,254,542 | current knowledg psoriasi covid pandem psoriasi chronic inflammatori diseas associ defect epiderm barrier immun system alreadi activ lesion site skin thus possibl affect individu differ immunolog rate viral respons especi import era novel coronavirus diseas covid affect entir world patient psoriasi often receiv system therapi includ immunosuppress biolog therapi new infecti diseas rais concern among dermatologist regard psoriasi treatment risk factor psoriasi obes diabet mellitus hypertens diseas link negat outcom higher sever covid psoriasi mediat inflammatori cell proinflammatori cytokin il il ifn tnf patient skin diseas shown suscept covid infect less sever diseas cours anti inflammatori agent vitamin could play signific role futur possibl treatment reduc risk sever psoriasi covid suggest patient treat biolog therapi continu treatment shown caus sever complic covid diseas prevent measur includ vaccin taken minim risk infect sever clinic outcom | D000086382;D011565 | T047;T067 |
36,254,541 | import multidisciplinari approach patient long term multisystem manifest unrecogn hereditari hemorrhag telangiectasia hereditari hemorrhag telangiectasia hht also call rendu osler weber syndrom rare autosom domin multisystem vascular disord character widespread mucocutan teleangiectasia frequent viscer arterioven malform avm tendenc bleed diagnosi suspect dermatolog patient general mucocutan vascular lesion site predilect associ frequent epistaxi posit famili histori aim paper emphas import multidisciplinari approach role time cooper dermatologist otorhinolaryngologist earli clinic recognit diagnosi diseas present famili case year old patient typic clinic featur hht long stand multisystem complic unrecogn diseas | D001165;D013683 | T019;T047 |
36,254,540 | factor associ earli referr pediatr cutan leishmaniasi determin earli referr healthcar provid may use health polici investig pediatr cutan leishmaniasi multivari analys aim explor determin earli healthcar seek children cutan leishmaniasi record children cutan leishmaniasi admit hospit adana turkey review effect age sex residenti distanc lesion number faciocerv onset earli referr evalu multivari logist regress analys mean durat diseas month earli referr signific like patient age year odd ratio respect patient age year borderlin signific associ present faciocerv onset earli referr younger children might due fact younger child greater parent concern child health problem rate late referr older children may decreas school base health intervent | D016773 | T047 |
36,254,539 | mucocutan melanoma diagnost therapeut problem mucos melanoma call mucos oral melanoma rare serious diagnost therapeut problem primari mix mucocutan form melanoma affect mucosa adjac skin also particular problemat rare given stage diagnosi treatment mucos oral melanoma differ cutan melanoma stage mix melanoma primari mucocutan melanoma well decis subsequ diagnost therapeut step individu modifi accord recommend respect two classif cutan also mucos melanoma time least larg extent overlap practic follow paradox occur stage melanoma tumor thick differ stage treat differ consensus base way time would appropri surgic intervent accord patient wish minim traumareduc risk develop facial disproport present case year old patient newli develop lesion area mucosa upper lip adjac skin identifi primari mucocutan form melanoma surgic remov complex pathogenesi diseas discuss herein emphas role uv radiat iatrogen immunosuppress mycophenol mofetil tacrolimus prednisolon due sever glomerulonephr lead kidney transplant well potenti possibl specul pathogenet role acetyl salicyl acid etc primari mucos mucocutan form melanoma remain challeng clinician step diagnosi treatment express multidisciplinari consensu solut | D008545;D009062;D012878 | T191 |
36,254,537 | parent attitud toward vaccin adolesc sexual health cross section studi posit parent role model protect factor adolesc sexual reproduct health srh aim investig parent opinion adolesc srh vaccin well sociodemograph determin child parent communic regard srh nation repres cross section telephon survey random stratifi sampl includ parent croatia mother least one child year age stratif perform region b size settlement differ found parent belief regard qualiti safeti efficaci vaccin potenti hazard effect although confirm child vaccin accord nation program vaccin option self paid vaccin exclud human papillomavirus almost everi third parent acquaint srh common father prefer sourc inform parent regard srh friend follow media profession healthcar sourc communic adolesc report respond parent claim child accur knowledg regard srh studi confirm predomin posit parent attitud vaccin communic adolesc regard srh emphas import effect parent engag indic need educ intervent strengthen knowledg immun srh | D000074384;D014612 | T121;T129;T032;T116 |
36,254,532 | impact covid pandem biomed public citat frequenc coronavirus diseas covid pandem result enorm relat public howev citat frequenc document influenc journal impact factor jif well examin aim evalu impact covid biomed research public citat frequenc | D000086382;D058873 | T047;T067 |
36,254,531 | first systemat gastroscopi train program surgeon korea endoscop evalu stomach essenti preoper plan post surgic surveil various diseas stomach includ malign gastroscopi educ program surgeon current infanc systemat organ korea studi aim introduc first systemat gastroscopi educ program surgeon korea | D005773;D066231 | T060;T097;T061 |
36,254,530 | neutrophil lymphocyt ratio monocyt lymphocyt ratio accord radiolog sever mycobacterium avium complex pulmonari diseas date studi investig whether neutrophil lymphocyt ratio nlr monocyt lymphocyt ratio mlr clinic valu mycobacterium avium complex mac pulmonari diseas pd | D008171;D015270 | T047 |
36,254,529 | nationwid survey pediatr gastrostomi tube placement korea various method implement pediatr gastrostomi tube placement aim investig perform status pediatr gastrostomi south korea present indic appropri method domest situat | D005774;D010372 | T061;T091 |
36,254,525 | antimicrobi stewardship solid organ transplant recipi current challeng propos metric solid organ transplant sot recipi challeng popul antimicrobi stewardship intervent due varieti reason includ immunosuppress consequ risk opportunist donor deriv infect high rate infect multi drug resist organ mdros clostridioid difficil need prolong antimicrobi prophylaxi despit data stewardship intervent metric address distinct need patient limit | D000890;D000073602;D018380;D009696;D016377 | T061;T121;T123;T114;T058 |
36,254,524 | audit tool antimicrobi prescrib solid organ transplant recipi assess current option antimicrobi stewardship am aim optim antimicrobi use audit report antimicrobi prescrib essenti audit tool solid organ transplant sot patient tailor need | D000900;D000890;D016377 | T061;T121;T195 |
36,254,523 | antimicrobi stewardship solid organ transplant perspect veteran affair medic center import antimicrobi stewardship am activ specif focus solid organ transplant sot recipi increas recogn veteran health administr vha creat nation guidanc commit resourc establish am program veteran affair va medic center across countri howev am implement discret individu va center | D000073602;D016377;D019737;D014728 | T061;T098;T025;T024;T023;T058 |
36,254,522 | beta lactam allergi surgic site infect prophylaxi solid organ transplant recipi singl center retrospect cohort studi beta lactam allergi blas common hospit patient includ transplant recipi bla associ decreas use prefer surgic site infect ssi prophylaxi increas ssis studi transplant popul | D006967;D016377 | T061;T046 |
36,254,521 | effect report beta lactam allergi pneumonia outcom lung transplant recipi effect report beta lactam allergi clinic outcom understudi lung transplant recipi evalu report beta lactam allergi clinic outcom popul | D058186;D003015;D004342;D006967;D011014 | T047;T046;T050;T037 |
36,254,520 | bridg gap approach report antimicrobi stewardship metric specif solid organ transplant recipi studi seek describ inpati antimicrobi use au util nation healthcar safeti network au nhsn au framework among solid organ transplant recipi sotr within month transplant | D000073602;D016360;D003015;D016030;D016377 | T061;T007;T037;T058;T047 |
36,254,519 | outpati peri oper antibiot stewardship solid organ transplant consequ inappropri antimicrobi use includ resist increas recogn global public health threat mani step taken last decad advanc antimicrobi stewardship initi organ transplant center current part institut activ antimicrobi stewardship program | D000890;D000073602;D016377 | T061;T121;T058 |
36,254,518 | dissemin implement scienc antimicrobi stewardship solid organ transplant perspect recipi solid organ transplant sot uniqu risk infect provid often hesit appli principl antimicrobi stewardship patient popul due perceiv excess risk method implement scienc may move field forward simultan improv patient outcom patient safeti | D000073602;D016377 | T061;T058 |
36,254,517 | antimicrobi stewardship program solid organ transplant recipi switzerland antimicrobi stewardship program asp essenti minim emerg antimicrobi resist improv patient outcom current status asp field organ transplant switzerland well character | D000073602;D016377 | T061;T058 |
36,254,516 | comput antimicrobi useantimicrobi resist ratio novel way assess inpati antimicrobi util use current nation healthcar safeti network metric current method benchmark inpati antimicrobi use au could benefit combin au antimicrobi resist ar inform provid metric benchmark microbiolog data may yield instruct better risk adjust measur au ar isol | D000890;D000086382;D017576;D055624 | T121;T007;T116;T067;T047;T195 |
36,254,515 | challeng opportun stewardship among solid organ transplant recipi candida auri bloodstream infect candida auri emerg nosocomi pathogen worldwid howev littl publish manag c auri solid organ transplant recipi | D016469;D016377 | T061;T047 |
36,254,514 | delabel penicillin antibiot allergi solid organ transplant patient immunocompromis popul includ solid organ transplant sot recipi high likelihood need antibiot therapi treatment infect well prophylaxi antibiot allergi common report often lead use altern second line antibiot associ poor outcom increas advers effect higher cost formal allergi assess allergi test serv import antimicrobi stewardship tool optim antibiot regimen patient popul | D000900;D004342;D016377 | T061;T121;T046;T195 |
36,254,513 | current state antimicrobi stewardship solid organ transplant israel aim review current state challeng need antimicrobi stewardship program asp adult solid organ transplant sot center israel | D000073602;D016377 | T061;T058 |
36,254,512 | shorter better case short antibiot cours common infect solid organ transplant recipi prolong antibiot associ toxic select resist organ secondari infect clostridioid difficil coliti emerg clinic data suggest short cours antibiot use common bacteri infect among immun compet patient mani random control trial rcts immunocompromis patient includ solid organ transplant recipi sotr exclud | D001424;D016377 | T061;T047 |
36,254,511 | brazilian perspect antimicrobi stewardship solid organ transplant incid multidrug resist organ mdros infect among solid organ transplant sot patient high brazil | D000073602;D016377;D065507 | T061;T058;T007 |
36,254,510 | diagnost stewardship possibl solid organ transplant diagnost stewardship solid organ transplant sot recipi potenti help vulner patient risk test overtreat | D016360;D016377;D019737 | T061;T007;T025;T024;T023 |
36,254,509 | current state antimicrobi stewardship organ transplant thailand antimicrobi stewardship am coher set action optim antimicrobi use improv patient outcom reduc antimicrobi resist amr thailand nation strateg plan includ am sinc due increas risk infect amr solid organ transplant sot recipi benefit antimicrobi stewardship program asp howev am sot well defin balanc asp need earli frequent antimicrobi treatment popul challeng review assess barrier potenti strategi am sot set thailand | D000890;D000073602;D016377 | T061;T121;T058 |
36,254,508 | transplant surgeon perspect antimicrobi stewardship experi transqip antimicrobi stewardship program asp shown reduc rate antimicrobi resist improv morbid mortal surgic patient asp larg underutil solid organ transplant program current state asp transplant review continu implement asp would like signific benefit transplant patient furthermor coupl asp robust programmat metric transplant specif nsqip hope lead improv outcom includ morbid mortal solid organ transplant recipi | D000073602;D016377;D066231 | T061;T058;T097 |
36,254,507 | could cell free dna host biomark assist antimicrobi stewardship organ transplant recipi antimicrobi stewardship solid organ transplant sot recipi import prevent antimicrobi associ complic tradit stewardship principl challeng implement sot patient newer methodolog optim stewardship effort need | D000890;D000073602;D000073888;D016377 | T061;T121;T123;T114;T058 |
36,254,506 | antifung stewardship solid organ transplant need antifung stewardship af lag behind antimicrobi stewardship am term implement evid base workforc experi solid organ transplant sot carri signific risk invas fungal infect high associ mortal therefor associ signific opportun optim antifung use | D000073602;D000072742;D016377 | T061;T058;T047 |
36,254,504 | japan perspect antimicrobi stewardship solid organ transplant current situat challeng opportun relat antimicrobi stewardship solid organ transplant sot patient japan well known | D000890;D000073602;D016377 | T061;T121;T058 |
36,254,503 | australian perspect antimicrobi stewardship program transplant solid organ close stem cell transplant perform annual australia | D000073602;D000072742 | T058;T047 |
36,254,502 | antibiot allergi label immunocompromis popul antibiot allergi label aal common report well defin preval general popul sever studi focus effort immunocompromis host understand preval report allergi label method antibiot allergi evalu delabel strategi potenti improv prescrib practic clinic outcom high antibiot use group review discuss current literatur preval impact evalu aal immunocompromis host focus beta lactam penicillin allergi sulfa antibiot antimicrobi sulfur allergi label | D004342 | T046 |
36,254,501 | rapid molecular test antimicrobi stewardship solid organ transplant sever molecular platform exist earli detect infecti pathogen review present current avail literatur summar clinic outcom use rapid diagnost test rdts solid organ transplant sot popul also present potenti benefit drawback technolog sot patient | D000890;D000073602;D016360;D016377 | T061;T121;T058;T007 |
36,254,500 | machin learn antimicrobi stewardship solid organ transplant futur use machin learn ml infecti diseas expand | D000890;D000073602;D003141;D016377 | T061;T121;T058;T047 |
36,254,493 | retrospect analysi common fault mainten strategi medic electron endoscop medic electron endoscop one indispens tool medic diagnosi treatment develop scienc technolog electron endoscop higher safeti accuraci tradit optic endoscop due sophist construct high price hospit spend lot money mainten everi year order prolong work life electron endoscop reduc incid artifici failur save hospit cost studi made retrospect analysi common fault electron endoscop summar mainten strategi refer | D004582;D019723 | T074;T091 |
36,254,492 | explor think fine manag cost account medic consum gradual advanc reform plan control high valu medic consum publish state council reform polici purchas quantiti charg consum zero bonus born oper pressur medic institut medic consum increas sharpli fine cost account manag demand improv due manag featur medic consum lead inaccur cross cycl cost account order achiev refin cost account manag relat busi system process adjust studi | D003132 | T078;T081;T097;T057 |
36,254,491 | analysi discuss problem found qualiti control medic devic clinic trial qualiti control problem institut level medic devic clinic trial hospit summar caus problem analyz perspect parti involv clinic trial improv measur discuss includ improv manag system strengthen train research optim select method strengthen respons regul conscious applic formul select basi applic aim ensur qualiti clinic trial provid refer clinic trial manag implement | D012107 | T062;T096;T170;T081;T169 |
36,254,490 | studi parametr releas ethylen oxid steril medic devic studi briefli introduc basic theori steril characterist ethylen oxid steril medic devic key factor steril effect analyz compar three method use product releas medic devic steril ethylen oxid test steril tradit releas parametr releas focus theoret basi feasibl valid requir advantag disadvantag parametr releas | D005027;D013242 | T131;T058;T109 |
36,254,489 | establish evalu system medic optic radiat protect eyewear kind class ii medic devic medic optic radiat protect eyewear meet requir safeti effect studi evalu system medic optic radiat protect eyewear establish combin medic devic registr unit divis guidelin classif method medic optic radiat protect eyewear given medic optic radiat protect eyewear assembl spectacl also special optic radiat protect perform perform evalu method medic optic radiat protect eyewear evalu method shelf life medic optic radiat protect eyewear given | D011835 | T061 |
36,254,488 | studi clear optic evalu method intraocular lens studi explor method determin diamet clear optic intraocular lens analyz design principl influenc factor clear optic measur compar clear optic diamet intraocular lens respect measur result two method good consist use measur clear optic consid accuraci conveni actual measur profil projector measur principl suitabl convent mass product test schlieren techniqu method provid use inform product develop featur descript stage use auxiliari verif method clear optic diamet measur | D007910 | T074 |
36,254,487 | studi character content determin method silver chitosan antibacteri gel character silver chitosan antibacteri gel establish method determin silver content sampl | D048271;D012834 | T121;T196;T109 |
36,254,486 | studi test method radiat emiss proton therapi equip electromagnet compat test proton therapi system differ tradit product anecho chamber high requir divis sampl composit understand applic standard formul oper mode select test locat test ambient nois accord requir gb standard test method radiat emiss proton therapi equip develop provid refer advic industri problem encount actual test studi | D061766 | T061 |
36,254,485 | research applic seismic perform medic imag equip view shortag research seismic perform medic imag equip paper investig summar seismic regulatori requir seismic test medic imag equip focus paramet select detect step result evalu detect equip requir seismic detect medic imag equip seismic test data medic imag equip various instal mode analyz seismic perform medic imag equip analyz summar | D003952 | T060 |
36,254,484 | develop applic medic devic recal event track system medic devic recal event track system design enabl user obtain recal earli warn inform relat medic devic time track system time obtain releas recal inform medic devic effect improv qualiti control hospit medic devic reduc use risk medic devic ensur life safeti patient | D057052;D011358 | T089;T062;T057 |
36,254,483 | sampl procedur inspect attribut applic field medic devic sampl inspect attribut one popular mean qualiti control medic devic widespread applic process product supervis gbt seri standard list differ type sampl procedur inspect attribut studi introduc gbt seri standard design index sampl scheme differ scenario time also provid suggest balanc accuraci economi provid guidanc applic medic devic manufactur regulatori depart | D003132 | T078;T081;T097;T057 |
36,254,482 | idea brief regulatori requir laboratori develop test us special kind vitro diagnost devicesivd laboratori develop testsldt great signific develop clinic laboratori studi aim explor regulatori requir idea ldts introduc develop ldts chang regulatori requir unit state comb current regulatori framework discuss relev idea regulatori requir ldts | D064790 | T058 |
36,254,481 | characterist clinic applic common use wound dress patholog mechan wound heal complic affect multipl factor modern wound dress wide use clinic manag wound heal achiev good therapeut effect clinic wound often caus differ etiolog howev review focus select reason dress differ type wound studi main focus characterist common use wound dress summar characterist common use wound dress clinic practic effect advantag disadvantag patholog wound diabet foot ulcer pressur injuri burn leg ulcer review studi aim provid refer develop clinic select wound dress scientif research first line nurs staff engag wound dress | D047070;D017719 | T122;T074;T047 |
36,254,480 | research progress magnet anchor abdomin video system magnet anchor technolog provid new develop opportun current minim invas surgeri magnet anchor abdomin video system base technolog effect improv oper minim invas singl port laparoscop surgeri develop histori magnet anchor abdomin video system review design featur defici various type magnet anchor video devic compar analyz evolut characterist magnet anchor video system explain minim invas intellig perspect challeng opportun magnet anchor video system summar prospect | D010535 | T060;T061 |
36,254,479 | develop applic first carbon ion therapi system china present heavi ion ideal radiat cancer treatment carbon ion use treatment mani kind cancer due higher relat biolog effect valu wuwei heavi ion center built first medic heavi ion acceler carbon ion radiotherapi system china obtain registr licens nation medic product administr offici receiv cancer patient march studi introduc develop applic first carbon ion radiotherapi system china | D063193;D020450;D009369 | T061;T196;T191 |
36,254,478 | design new punctur needl trocar develop new type punctur needl indwel needl overcom perform problem exist punctur needl reduc produc cost enhanc clinic oper | D009339;D011677 | T060;T058;T074 |
36,254,477 | design valid accuraci assess tool algorithm optic posit system surgic navig precis optic posit system one import factor affect precis navig guid surgeri studi effici low cost tool algorithm propos evalu accuraci optic posit system base ablat scenario liver cancer two valid experi design experiment result show tool algorithm evalu accuraci current posit system accur effici | D008113;D055096;D025321 | T061;T191;T073 |
36,254,476 | develop intellig multifunct knee joint function exercis equip develop intellig equip perform multipl mode function exercis knee joint accur measur control strength angl angular veloc time frequenc | D007719 | T030 |
36,254,475 | research hospit oper room manag system base pda code scan technolog view high recognit error rate long scan time exist hospit scan technolog new hospit oper room scan system design base person digit assist pda pda scan devic adopt picfa microcontrol bit wireless transmiss rfid bluetooth technolog code scan effici great improv addit order improv accuraci imag analysi studi also adopt energi driven sampl classif algorithm ed ca proper preprocess medic data inform receiv pda scan construct function classifi improv imag process effici accord ed ca reduct process experiment result show averag accuraci code scan system design studi prove pda code scan good perform | D034201;D009873 | T073;T093 |
36,254,474 | conveni approach improv correl geometri dosimetr paramet automat segment radiotherapi design seri geometr index improv correl geometr paramet dosimetr paramet | D058958;D050397 | T061;T029 |
36,254,473 | fpga implement digit coordin convers intravascular ultrasound imag system base cordic algorithm order facilit doctor better obtain cardiovascular imag use intravascular ultrasound imag system make accur diagnosi digit coordin convers method intravascular ultrasound imag system base cordic algorithm propos convert polar coordin rectangular coordin angular rotat orient calcul experiment simul test carri platform intravascular ultrasound imag system fpga experiment simul show cordic algorithm effect output sine cosin valu compar tradit tabl find method algorithm faster speed stronger real time perform need less hardwar resourc suitabl intravascular ultrasound imag system | D000465;D003201 | T170;T073 |
36,254,472 | non contact blood pressur measur method use frequenc modul continu wave radar non contact continu blood pressur monitor signific vital sign monitor frequenc modul continu wave fmcw radar suitabl non contact wave signal extract heartbeat guid blood pressur monitor algorithm use fmcw radar propos | D011825;D012815 | T073;T066 |
36,254,471 | bowel sound detect method experi base multi featur combin bowel sound import indic monitor reflect intestin motor function tradit manual auscult requir high profession knowledg rich clinic experi doctor addit long time auscult time consum labori may lead misjudg caus subject error solv problem first wavelet transform use preprocess bowel sound signal nois reduct enhanc second three typic featur intestin sound extract accord combin featur three stage decis design carri multi paramet multi featur joint threshold detect algorithm realiz detect bowel sound signal locat start end point make possibl complet bowel sound signal extract effect studi larg number clinic data label bowel sound collect new effect evalu method propos verifi propos method accuraci rate result studi provid systemat support theoret guarante diagnosi intestin diseas monitor postop intestin function recoveri patient | D001314;D012815 | T060;T066 |
36,254,467 | pc phos enabl catalyt palladium heteroallyl asymmetr cycloaddit asymmetr cycloaddit reaction power tool expediti construct enantioenrich cyclic motif organ chemistri sharp contrast well develop cycloaddit reaction via palladium trimethylenemethan pd tmm intermedi hetero cycloaddit heteroallyl cation remain rare larg due thermal forbidden natur best knowledg exampl asymmetr version lead enantioenrich heterocycl report far herein enabl first exampl catalyt asymmetr cycloaddit electrophil palladium heteroallyl zwitterion intermedi pd otmm pd ntmm cyclic acycl dien via pathway termin c n c bond format deliv high substitut fuse pyrrolidin tetrahydrofuran ring high yield excel regio diastereo enantioselect engin pc phos one chiral sulfinamid phosphin sadpho type ligand introduc di tert butyl orand difluorophenyl group vital compon achiev excel catalyt reactiv enantioselect | D010165;D011759 | T196;T109 |
36,254,466 | microfluid outer blood retin barrier model induc wet age relat macular degener hypox stress wet age relat macular degener amd sever ophthalm diseas develop outer blood retin barrier obrb involv two type cell retin pigment epithelium rpe choriocapillari endothelium cce unfortun pathogenesi amd unclear risk effect therapi anti vegf inject consist argu also sinc obrb hard observ vivo vitro model patholog studi necessari propos advanc obrb model enhanc two major way fulli vascular cce vivo analog distanc rpe cce model consist rpe arp monolay adjac cce huvec embed fibrin gel microfluid chip requir four day construct obrb notabl intercellular distanc tune vivo scale without extran scaffold thus two cell layer interact freeli extracellular matrix ecm vivo signific wet amd main develop broken intercellular interact thank vivo similar model incub hypox condit similar oxygen induc retinopathi anim model show upregul vascular compar amd condit envisag model use assist investig amd | D008268;D057135 | T047 |
36,254,464 | applic n n dimethylethanolamin one carbon synthon synthesi pyrrolo quinoxalin quinazolin one benzo imidazoquinazolin via annul synthesi n heterocycl compos signific part synthet chemistri report cu ii catalyz green effici synthesi pyrrolo quinoxalin quinazolin one benzo imidazoquinazolin deriv develop employ n n dimethylethanolamin dmea c synthon green oxid critic transform facilit format key intermediatea reactiv iminium ion method conduct mild condit compat divers function group provid appeal altern previous develop protocol | D011810;D003642 | T121;T109 |
36,254,462 | discoveri optim quinolin analogu novel potent antivir enterovirus enterovirus ev nonpolio enterovirus main transmit respiratori rout pose potenti threat larg scale spread ev infect most caus moder sever respiratori diseas children potenti induc neurolog diseas howev specif antivir drug vaccin ev herein virtual screen ration design seri novel quinolin analogu anti ev agent target vp identifi particular exhibit potent antivir activ ec valu rang various ev strain show inhibit viral replic verifi western blot immunofluoresc plaqu format assay mechanist studi indic anti ev agent work main interact vp accept bioavail rat signific metabol stabil human liver microsom cl int mlminkg min indic compound novel scaffold worth investig | D030016;D004769;D004770;D011804;D012141 | T005;T109;T047 |
36,254,460 | altern caregiv role food choic young children semi urban urban mexico altern caregiv ie someon besid primari caregiv also take care children make food choic children studi investig altern caregiv consid make food choic children perspect role make food choic feed children depth interview conduct altern caregiv children age year old semi urban urban area state mexico mexico interview record transcrib code analyz use constant compar method altern caregiv describ space situat expos children food care altern caregiv spent longer period time child describ involv child ate healthi nutriti food cost food affect children import consider altern caregiv decid feed child altern caregiv substanti role child feed decis cook advis mother feed children effort promot healthi food choic children includ target altern caregiv | D017028;D005518 | T098;T080;T055;T099;T097 |
36,254,458 | cyanidin chlorid improv lps induc depress like behavior mice amelior hippocamp inflamm excitotox depress global diseas place signific burden human health neuroinflamm disturb glutam metabol brain region hippocampus play vital role develop depress previous studi shown cyanidin chlorid cycl anti inflammatori antioxid properti neuroprotect effect peripher tissu howev effect cycl depress possibl mechan compound target brain region remain less elucid investig role cycl lipopolysaccharid lps induc depress examin influenc drug central inflamm express excitatori amino acid transport hippocampus found prophylact ip applic cycl mgkg day signific reduc immobl time assess tail suspens test tst forc swim test fst lps challeng mice suggest effect antidepress activ drug western blot immunofluoresc stain hippocampus reveal cycl inhibit upregul proinflammatori cytokin includ tnf il suppress hyperact microglia induc lps indic anti inflammatori role hippocampus moreov treatment cycl also recov downregul express glial fibrillari acid protein gfap brain deriv neurotroph factor bdnf glutam aspart transport glast excitatori amino acid transport eaat two member excitatori amino acid transport famili role cycl also verifi cultur bv u cell conclus present vivo vitro studi demonstr cycl exert potent antidepress action lps induc depress model under mechan associ reduc hippocamp inflamm improv neurotroph function attenu excitotox induc glutam | D008070;D003863 | T184;T048;T109 |
36,254,448 | thoma willi legaci th anniversari birth celebr th anniversari birth thoma willi main contribut develop neurosci particular neurolog present willi coin term neurolog contribut signific field neuroanatomi descript arteri circl locat base brain bear name also describ striatum cranial nerv furthermor clinic neurologist willi particip descript various diseas includ myasthenia gravi restless leg syndrom | D009462;D009488 | T091 |
36,254,447 | brazilian practic guidelin stroke rehabilit part ii brazilian practic guidelin stroke rehabilit part ii develop scientif depart neurolog rehabilit brazilian academi neurolog academia brasileira de neurologia portugues focus specif rehabilit techniqu aid recoveri impair disabl stroke part part ii also base recent avail evid random control trial systemat review meta analys guidelin part ii cover disord communic dysphagia postur control balanc ataxia spastic upper limb rehabilit gait cognit unilater spatial neglect sensori impair home rehabilit medic adher palliat care cerebrovascular event relat sever acut respiratori syndrom coronavirus sar cov infect futur stroke rehabilit stroke websit support patient caregiv goal provid health profession recent knowledg recommend better rehabilit care stroke | D020521;D000071939 | T061;T047 |
36,254,446 | reduc care time implement protocol acut ischem stroke systemat review treatment acut ischem stroke cerebr reperfus therapi requir rapid care recognit symptom | D000083242 | T047 |
36,254,445 | would better dead investig suicid ideat peopl epilepsi known risk suicid behavior adult peopl epilepsi pwes high howev associ clinic psychosoci factor still discuss | D004827;D059020 | T033;T047 |
36,254,444 | neuromuscular diseas social distanc result covid pandem coronavirus sever acut respiratori syndrom sar cov generic call covid classifi pandem world health organ made health practic around world face uniqu challeng sinc physic distanc measur confin adopt differ govern control human human transmiss distanc affect treatment individu progress diseas neuromuscular diseas nmds | D000086382;D009468 | T019;T047;T067 |
36,254,443 | flow volum measur arteri venous cerebrospin fluid patient multipl sclerosi multipl sclerosi ms usual describ autoimmun diseas although exact mechan diseas remain unknown studi report venous flow abnorm may involv pathogenesi ms mani associ clinic manifest | D009103;D020529 | T047 |
36,254,442 | brain volum loss physic cognit impair naiv multipl sclerosi patient treat fingolimod prospect cohort studi bueno air argentina percentag brain volum loss pbvl classic consid biomark multipl sclerosi ms | D060825;D009103;D020529 | T047;T048 |
36,254,441 | autonom cardiorespiratori respons activ tilt test individu parkinson diseas cross section studi parkinson diseas pd frequent associ autonom dysfunct howev data regard influenc pd autonom respons postur chang limit | D010300 | T047 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.